{"groups":[{"description":"Platinum-based chemotherapy (paclitaxel and carboplatin) every 3 weeks (Q3W) for a maximum of 6 cycles with durvalumab placebo (intravenous \\[IV\\]) Q3W.\n\nFollowing completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) every 4 weeks (Q4W) and olaparib placebo (tablets) twice daily (bd) orally as maintenance treatment until disease progression.","id":"FG000","title":"Standard of Care (SoC)"},{"description":"Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W.\n\nFollowing completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.","id":"FG001","title":"SoC + Durvalumab"},{"description":"Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W.\n\nFollowing completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.","id":"FG002","title":"SoC + Durvalumab + Olaparib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"72"},{"groupId":"FG001","numSubjects":"54"},{"groupId":"FG002","numSubjects":"49"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"25"},{"groupId":"FG002","numSubjects":"18"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"241"},{"groupId":"FG001","numSubjects":"238"},{"groupId":"FG002","numSubjects":"239"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"147"},{"groupId":"FG001","numSubjects":"159"},{"groupId":"FG002","numSubjects":"170"}],"comment":"Patients ongoing study at time of primary PFS analysis DCO: 12 Apr 2023","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"94"},{"groupId":"FG001","numSubjects":"79"},{"groupId":"FG002","numSubjects":"69"}],"type":"NOT COMPLETED"}],"title":"Global Cohort"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"11"},{"groupId":"FG002","numSubjects":"13"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"4"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"44"},{"groupId":"FG001","numSubjects":"43"},{"groupId":"FG002","numSubjects":"42"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"29"},{"groupId":"FG002","numSubjects":"24"}],"comment":"Patients ongoing study at time of primary PFS analysis DCO: 08 Jul 2024","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"18"}],"type":"NOT COMPLETED"}],"title":"China Cohort"}],"preAssignmentDetails":"It was planned that approximately 699 women from the Global cohort and 129 women from the China cohort, with newly diagnosed advanced or recurrent endometrial cancer, were to receive durvalumab/placebo in combination with platinum-based chemotherapy followed by maintenance durvalumab/placebo (same treatment as during chemotherapy phase) and olaparib/placebo in a 1:1:1 ratio.","recruitmentDetails":"Global Cohort: 875 patients screened across 179 centres in 22 countries; 718 were randomised. Results were reported for analysis of progression-free survival (PFS) (data cut-off \\[DCO\\]: 12 Apr 2023).\n\nChina Cohort: 172 patients screened across 25 sites; 129 were randomized. Results were reported for analysis of PFS (DCO: 08 Jul 2024).\n\nIn total, 805 patients were randomised; 718 to the Global cohort, 129 to the China cohort, with 42 patients overlapping and belonging to both cohorts."}